News & analysis
Times are shown in GMT+11, values are delayed by at least 15 minutes. Past performance is not a reliable indicator of future results.
Dimerix Ltd is a biopharmaceutical company developing innovative new therapies in areas with unmet medical needs. The company is developing five product candidates: DMX-200 for FSGS; DMX-200 for diabetic kidney disease; DMX-200 for COVID-19 pneumonia patients in ICU; DMX-200 for respiratory complications in Covid-19 patients; and DMX-700 for COPD; as well as the proprietary ReceptorHIT assay technology.Dimerix Ltd is a clinical stage biotechnology company. The company is focused on developing new therapeutics discovered using its proprietary drug development platform, Receptor-Heteromer Identification Technology (HIT).
Latest DXB News